Chief Scientific Officer & Chief Operating Officer Pad Chivukula of Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) sold 26,000 shares of the company on June 3, 2024, as reported in a recent SEC Filing.
Arcturus to present new Phase 1b interim data for ARCT-032 at European Cystic Fibrosis Conference on June 7, 2024
First four CF patients demonstrated an average improvement of 4% FEV1 after two...
Arcturus Therapeutics Holdings Inc. announced ARCT-032 will be presenting Phase 1 results in healthy volunteers and new Phase 1b interim data in CF patients for ARCT-032, an inhaled investigational...
Why Is Arcturus Therapeutics Stock Trading Higher On Tuesday? biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.
Arcturus Therapeutics (NASDAQ:ARCT) Trading 5.8% Higher tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Combines Achilles' best-in-class AI-driven, tumor-targeting technology with Arcturus' world-leading self-amplifying mRNA platform Combined technologies have the potential to generate potent and durable